Top

Published in:

01-08-2015 | Original Article

Cytokine production in patients with papillary thyroid cancer and associated autoimmune Hashimoto thyroiditis

Authors: Snezana Zivancevic-Simonovic, Olgica Mihaljevic, Ivana Majstorovic, Suzana Popovic, Slavica Markovic, Olivera Milosevic-Djordjevic, Zorica Jovanovic, Ljiljana Mijatovic-Teodorovic, Dusan Mihajlovic, Miodrag Colic

Published in: Cancer Immunology, Immunotherapy | Issue 8/2015

Abstract

Hashimoto thyroiditis (HT) is the most frequent thyroid autoimmune disease, while papillary thyroid cancer (PTC) is one of the most common endocrine malignancies. A few patients with HT also develop PTC. The aim of this study was to analyze cytokine profiles in patients with PTC accompanied with autoimmune HT in comparison with those in patients with PTC alone or HT alone and healthy subjects. Cytokine levels were determined in supernatants obtained from phytohemagglutinin (PHA)-stimulated whole blood cultures in vitro. The concentrations of selected cytokines: Th1—interferon gamma (IFN-γ); Th2—interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 10 (IL-10) and interleukin 13 (IL-13); Th9—interleukin 9 (IL-9); and Th17—interleukin 17 (IL-17A) were measured using multiplex cytokine detection systems for human Th1/Th2/Th9/Th17/Th22. We found that PTC patients with HT produced significantly higher concentrations of IL-4, IL-6, IL-9, IL-13 and IFN-γ than PTC patients without HT. In conclusion, autoimmune HT affects the cytokine profile of patients with PTC by stimulating secretion of Th1/Th2/Th9 types of cytokines. Th1/Th2 cytokine ratios in PTC patients with associated autoimmune HT indicate a marked shift toward Th2 immunity.

Dayan CM, Daniels GH (1996) Chronic autoimmune thyroiditis. N Engl J Med 335:99–107PubMedCrossRef

Mazziotti G, Sorvillo F, Naclerio C et al (2003) Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto’s thyroiditis. Eur J Endocrinol 148:383–388PubMedCrossRef

Figueroa-Vega N, Alfonso-Pérez M, Benedicto I et al (2010) Increased circulating proinflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis. J Clin Endocrinol Metab 2010(95):953–962CrossRef

Skapenko A, Niedobitek GU, Kalden JR et al (2004) Generation and regulation of human Th1-biased immune responses in vivo: a critical role for IL-4 and IL-10. J Immunol 172:6427–6434PubMedCrossRef

Marazuela M, García-López MA, Figueroa-Vega N et al (2006) Regulatory T cells in human autoimmune thyroid disease. J Clin Endocrinol Metab 91:3639–3646PubMedCrossRef

Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167PubMedCrossRef

Riesco-Eizaguirre G, Santisteban P (2007) New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer 14:957–977PubMedCrossRef

Ozgen AG, Karadeniz M, Erdogan M et al (2009) The (-174) G/C polymorphism in the interleukin-6 gene is associated with risk of papillary thyroid carcinoma in Turkish patients. J Endocrinol Invest 32:491–494PubMedCrossRef

Cunha LL, Aj Tincani, Assumpcao LV et al (2011) Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer. Clinics (Sao Paulo) 66:1203–1208CrossRef

10.

Simonovic SZ, Mihaljevic O, Majstorovic I et al (2015) Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer: elevated Th2/Th9 production before and reduced Th2 cytokine production after radioactive iodine therapy. Cancer Immunol Immunother 64:75–82PubMedCrossRef

11.

Stassi G, Todaro M, Zerilli M et al (2003) Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 63:6784–6790PubMed

12.

Jankovic B, Le KT, Hershman JM (2013) Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab 98:474–482PubMedCrossRef

13.

Weber F (2014) Lymphocytes and thyroid cancer: more to it than meets the eye? Endocr Relat Cancer 21:C1–C5PubMedCrossRef

14.

Cunha LL, Marcello MA, Ward LS (2014) The role of the inflammatory microenvironment in thyroid carcinogenesis. Endocr Relat Cancer 21:R85–R103PubMedCrossRef

15.

Kashima K, Yokoyama S, Noguchi S et al (1998) Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 8:197–202PubMedCrossRef

16.

Singh B, Shaha AR, Trivedi H et al (1999) Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: impact of presentation, management and outcome. Surgery 126:1070–1077PubMedCrossRef

17.

Kim EY, Kim WG, Kim WB et al (2009) Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 71:581–586CrossRef

18.

Lee JH, Kim Y, Choi JW et al (2013) The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol 168:343–349PubMedCrossRef

19.

Kebebew E, Treseler P, Ituarte P, Clark O (2001) Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 25:632–637PubMedCrossRef

20.

Cunha LL, Ward LS (2012) Concurrent lymphocytic thyroiditis is associated to less aggressive papillary thyroid carcinomas. Eur Arch Otorhinolaryngol 269:699–700PubMedCrossRef

21.

Schuetz M, Duan H, Wahl K et al (2006) T Lymphocyte cytokine production patterns in Hashimoto patients with elevated calcitonin levels and their relationship to tumor initiation. Anticancer Res 26:4591–4596PubMed

22.

Nikiforov YE (2012) Thyroid tumors: classification, staging, and general considerations. In: Nikiforov YE, Biddinger PW, Thompson LDR (eds) Diagnostic pathology and molecular genetics of the thyroid, 2nd edn. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, pp 108–119

23.

Budhu A, Wang XW (2006) The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 80:1197–1213PubMedCrossRef

24.

Bodelon C, Polley MY, Kemp TJ et al (2013) Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. Ann Oncol 24:2073–2079PubMedCentralPubMedCrossRef

25.

Ellyard JI, Simson L, Parish CR (2007) Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens 70:1–11PubMedCrossRef

26.

Mattes J, Hulett M, Xie W et al (2003) Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 197:387–393PubMedCentralPubMedCrossRef

27.

Roy M, Chen H, Sippel RS (2013) Current understanding and management of medullary thyroid cancer. Oncologist 18:1093–1100PubMedCentralPubMedCrossRef

28.

Schroder K, Hertzog PJ, Ravasi T et al (2004) Interferon-Υ: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163–189PubMedCrossRef

29.

Del Prete GF, Tiri A, Mariotti S et al (1987) Enhanced production of gamma-interferon by thyroid-derived T cell clones from patients with Hashimoto’s thyroiditis. Clin Exp Immunol 69:323–331PubMedCentralPubMed

30.

Zaidi MR, Merlino G (2011) The two faces of interferon-Υ in cancer. Clin Cancer Res 17:6118–6124PubMedCentralPubMedCrossRef

31.

Miller CH, Maher SG, Young HA (2009) Clinical use of interferon-gamma. Ann N Y Acad Sci 1182:69–79PubMedCrossRef

32.

Hossain MS, Bhimani C, Zhengjia C et al (2011) Profiling counter-regulatory and cytotoxic immune pathways with cellular biomarkers in thyroid cancer patients. [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2–6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 71(8 Suppl):Abstract nr 5525. doi:10.1158/1538-7445.AM2011-5525

33.

Kang S, Tanaka T, Kishimoto T (2015) Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol 27:21–29PubMedCrossRef

34.

Kimura A, Kishimoto T (2010) IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40:1830–1835PubMedCrossRef

35.

Baki M, Akman FE, Vural P et al (2012) The combination of interleukin-10 -1082 and tumor necrosis factor α -308 or interleukin-6 -174 genes polymorphisms suggests an association with susceptibility to Hashimoto’s thyroiditis. Int Immunopharmacol 12:543–546PubMedCrossRef

36.

Weetman AP, Bright-Thomas R, Freeman M (1990) Regulation of interleukin-6 release by human thyrocytes. J Endocrinol 127:357–361PubMedCrossRef

37.

Ajjan RA, Watson PF, Weetman AP (1996) Cytokines and thyroid function. Adv Neuroimmunol 6:359–386PubMedCrossRef

38.

Ruggeri RM, Sciacchitano S, Vitale A et al (2009) Serum hepatocyte growth factor (HGF) is increased in Hashimoto’s thyroiditis whether or not it is associated with nodular goiter as compared with healthy non-goitrous individuals. J Endocrinol Invest 32:465–469PubMedCrossRef

39.

Sieminska L, Wojciechowska C, Kos-Kudla B et al (2010) Serum concentrations of leptin, adiponectin, and interleukin-6 in postmenopausal women with Hashimoto’s thyroiditis. Endokrynol Pol 61:112–116PubMed

40.

Sehgal PB (1990) Interleukin 6 in infection and cancer. Proc Soc Exp Biol Med 195:183–191PubMedCrossRef

41.

Kura Y, De Velasco MA, Kobayashi Y, et al (2013) Interleukin-6 (IL-6) as a therapeutic target in prostate cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6–10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 73(8 Suppl):Abstract nr 1226. doi:10.1158/1538-7445.AM2013-1226

42.

Zhang Y, Yan W, Collins MA et al (2013) Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res 73:6359–6374PubMedCrossRef

43.

Ujiie H, Tomida M, Akiyama H et al (2012) Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer. Anticancer Res 32:3251–3258PubMed

44.

Huang BY, Hseuh C, Chao TC et al (2011) Well-differentiated thyroid carcinoma with concomitant Hashimoto’s thyroiditis present with less aggressive clinical stage and low recurrence. Endocr Pathol 22:144–149PubMedCrossRef

45.

Ng TH, Britton GJ, Hill EV et al (2013) Regulation of adaptive immunity; the role of interleukin-10. Front Immunol 4:129–140PubMedCentralPubMed

46.

Smilek DE, Ehlers MR, Nepom GT (2014) Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech 7:503–513PubMedCentralPubMedCrossRef

47.

de Waal-Malefyt R, Yssel H, de Vries JE (1993) Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 150:4754–4765PubMed

48.

Cyktor JC, Turner J (2011) Interleukin-10 and immunity against prokaryotic and eukaryotic intracellular pathogens. Infect Immunol 79:2964–2973CrossRef

49.

Franks AL, Slansky JE (2012) Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 32:1119–1136PubMedCentralPubMed

50.

Luheshi N, Davies GC, Poon E et al (2013) Th1 and Th2 cytokines determine how CD40 activation changes human macrophage function in vitro. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6–10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 73(8 Suppl):Abstract nr 1542. doi:10.1158/1538-7445.AM2013-1542

51.

Becker JC, Andersen MH, Schrama D et al (2013) Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 62:1137–1148PubMedCrossRef

52.

Atsumi T, Singh R, Sabharwal L et al (2014) Inflammation amplifier, a new paradigm in cancer biology. Cancer Res 74:8–14PubMedCrossRef

53.

Murray JI, West NR, Murphy LC et al (2014) Intratumoral inflammation and endocrine resistance in breast cancer. Endocr Relat Cancer 22:R51–R67PubMedCrossRef

Title: Cytokine production in patients with papillary thyroid cancer and associated autoimmune Hashimoto thyroiditis
Authors: Snezana Zivancevic-Simonovic
Olgica Mihaljevic
Ivana Majstorovic
Suzana Popovic
Slavica Markovic
Olivera Milosevic-Djordjevic
Zorica Jovanovic
Ljiljana Mijatovic-Teodorovic
Dusan Mihajlovic
Miodrag Colic
Publication date: 01-08-2015
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 8/2015
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-015-1705-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2015

STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice

Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer

6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice

Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma: a phase 1 dose escalation clinical trial

Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation

CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion

Keynote webinar | Spotlight on antibody–drug conjugates in cancer